Can COVID-19 cause, uncover or otherwise activate diabetes?

As many as 14% of patients with severe COVID-19 develop type I or type II diabetes––and doctors are bewildered by the association. 

Health experts aren’t even sure if the diabetes symptoms will subside once a person has gotten over COVID-19, because some patients seem to return to normal while others go home with “full-blown diabetes” after being treated for COVID-19, according to one Bethesda, Maryland-based doctor who described the phenomenon to the Washington Post. 

The diabetes trend seen among some severe COVID-19 patients is one on a long list of bizarre symptoms associated with the virus, which attacks the lungs but is also known to cause vascular problems, neurological disorders, and kidney and heart damage. Patients can also develop diabetes or elevated blood sugar levels, even if they have no history of diabetes, the Post reported, and scientists aren’t sure if the virus accelerates diseases already under the surface or if it actually causes them.

However, the association between diabetes and viruses has been seen before, including influenza and SARS. Underlying health issues, such as obesity or family history of diabetes, may play a role in COVID-19 patients who develop diabetes, but elevated blood glucose levels from a steroid used in COVID-19 treatment could also potentially be the culprit. Still, diabetes cases develop among patients with no such health issues or history and can even develop months after the virus has cleared the system.

A year into the COVID-19 pandemic, a group of diabetes experts has created a registry of 150 patients with COVID-19-related diabetes to monitor outcomes.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.